Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

A method according to 9, wherein said active ingredient is an A3-selective A3RAg that is a nucleoside derivative of the following general formula (I):

• wherein
• R1 is C1–C10 alkyl, C1–C10 hydroxyalkyl, C1–C10 carboxyalkyl or C1–C10 cyanoalkyl or a group of the following general formula (II):
• in which:
• Y is an oxygen or sulfur atom or CH2;
• X1 is H, C1–C10 alkyl, Ra Rb NC(═O)— or HORc—, wherein Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1–C10 alkyl, amino, C1–C10 haloalkyl, C1–C10 aminoalkyl, C1–C10 BOC-aminoalkyl, and C3–C10 cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and Rc is selected from the group consisting of C1–C10 alkyl, amino, C1–C10 haloalkyl, C1–C10 aminoalkyl, C1–C10 BOC-aminoalkyl, and C3–C10 cycloalkyl;
• X2 is H, hydroxyl, C1–C10 alkylamino, C1–C10 alkylamido or C1–C10 hydroxyalkyl;
• X3 and X4 each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, —OCOPh, —OC(═S)OPh or both X3 and X4 are oxygen connected to >C═S to form a 5-membered ring, or X2 and X3 form the ring of formula (III):
• where R′ and R″ are independently C1–C10 alkyl;
• R2 is selected from the group consisting of hydrogen, halo, C1–C10 alkylether, amino, hydrazido, C1–C10 alkylamino, C1–C10 alkoxy, C1–C10 thioalkoxy, pyridylthio, C2–C10 alkenyl;
• C2–C10 alkynyl, thio, and C1–C10 alkylthio;
• and
• R3 is a —NR4R5 group with R4 being hydrogen, alkyl, substituted alkyl or aryl-NH—C(Z)—, with Z being O, S or NRa, and, when R4 is hydrogen, R5 being selected from the group consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or anilide groups, each said group being unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C1–C10 alkyl, amino, halo, C1–C10 haloalkyl, nitro, hydroxyl, acetamido, C1–C10 alkoxy, and sulfonic acid or a salt thereof;
• or R5 being benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C1–C10 cycloalkyl;
• or R5 being a group of the following formula:
• or, when R4 is alkyl, substituted alkyl, or aryl-NH—C(Z)—, then R5 being selected from the group consisting of substituted or unsubstituted heteroaryl-NRa—C(Z), heteroaryl-C(Z)—, alkaryl-NRa—C(Z)—, alkaryl-C(Z)—, aryl-NR—C(Z)— and aryl-C(Z);
• or a suitable salt of the compound defined above.